Amedisys, a for-profit hospice and home health-care provider with four locations in New Hampshire, is shutting down its operations in Dover and Concord.
“Our local teams are working closely with the referring doctors, patients, and patients’ loved ones to help bridge them to other Amedisys care centers or assist them in finding another provider,” said company spokeswoman Kendra Kimmons from Amedisys headquarters in Louisiana.
“During this process, our absolute focus on quality care will stay at the forefront,” she said.
The Hyder House Hospice in Dover and the Beacon Hospice in Concord will consolidate with other Amedisys care centers, Kimmons said.
The company’s other New Hampshire locations are in Londonderry and Portsmouth. Amedisys also partners with Wentworth Home Care and Hospice in Dover.
Kimmons said the Dover and Concord locations were not meeting their financial targets and are part of a restructuring that is taking place across the country.
“We are closing or consolidating a number of care centers nationally that have not been performing as desired, and refocusing efforts on our well-performing care centers around the country, where we’ll continue delivering the highest quality, patient-centered care,” she said.
Amedisys operates more than 350 Medicare-certified home health care centers and approximately 90 Medicare-certified hospice care centers in the U.S.
Kimmons would not comment on the number of employees affected, but one employee in an email to the Union Leader said all staff at the two locations will be laid off.
“They decided on March 25 that they were going to layoff half of the workers the following Friday, and then on Wednesday announced the rest would be laid off by April 31,” the employee wrote.
Amedisys dispatched hospice nurses from Dover and Concord to facilities in Laconia and Boscawen that will now need to find new providers.
In January, the company agreed to pay $150 million to settle an investigation by the U.S. Department of Justice into its Medicare billing practices, going back to 2010.
Amedisys admitted no wrongdoing, according to a company statement, but agreed to pay the fine to close the matter.
“Higher cost per visit in home health, higher-than-expected employee healthcare cost and an accrual of $450,000 related to one of the company’s care centers were responsible for the company’s dismal bottom-line results in 2013,” according to the stock analysis service, Zachs.com.
“However, Amedisys is poised to gain from a solid foothold in the still untapped home health and hospice services market, which should catalyze growth,” the analyst wrote. “In addition, positive demographic trend is another upside.”